Taken together, these data strongly suggest that CCN2 is involved in DMD's pathophysiology and supports the ongoing clinical trial that is testing the use of anti-CCN2 antibodies in DMD patients (NCT02606136, NCT04371666). Here, CCN2 is linked to Duchenne muscular dystrophy.